Introduction:
Ori Biotech has launched its IRO platform, a next-generation platform designed to address the challenges in cell and gene therapy manufacturing. The announcement was made at the International Society for Cell & Gene Therapy’s annual conference. The IRO platform aims to improve patient access to these life-saving therapies by reducing labor, cost of goods, and processing times, and accelerating tech transfer times. It offers flexibility for early process development and scalability for GMP manufacturing.
- Ori Biotech has launched the IRO platform to overcome the manufacturing challenges in cell and gene therapies.
- The IRO platform aims to improve patient access to life-saving therapies by reducing labor, cost of goods, and processing times.
- It offers flexibility for early process development and scalability for GMP manufacturing.
- The platform has the potential to accelerate therapy development timelines and bring products to patients more quickly.
- Ori Biotech is focused on supporting and empowering the scientific community to increase patient access to cell therapies.
Conclusion:
Ori Biotech’s launch of the IRO platform is a significant development in the field of cell and gene therapy manufacturing. The platform addresses the key challenges of scalability and cost, which have limited patient access to these therapies. By reducing labor, cost of goods, and processing times, the IRO platform has the potential to accelerate therapy development timelines and make these life-saving treatments more accessible and affordable. Ori Biotech’s focus on supporting the scientific community reflects their commitment to advancing the field and improving patient outcomes. Overall, the launch of the IRO platform represents a promising advancement in the manufacturing of cell and gene therapies.
